LYNPARZA is a PARP inhibitor that takes advantage of DNA damage

LYNPARZA is a type of targeted therapy called a PARP inhibitor. It is a prescription oral treatment for adults who have an inherited BRCA mutation (also known as gBRCA or germline BRCA) and HER2-negative metastatic breast cancer that has been treated with chemotherapy, and if HR-positive, treated with hormonal therapy.

LYNPARZA is different from chemotherapy. It takes advantage of DNA damage so that cancer cells can’t get the help they need to survive. LYNPARZA can also affect healthy cells.



  • 1. Cancer cells grow quickly

    In breast cancer, cells in the breast grow out of control.

  • 2. Fast growth creates damage

    This growth creates damage that must be repaired in order for the cancer cells to keep growing.

  • 3. PARP helps fix damage

    One way to fix this damage is to use PARP, which is an enzyme that has many jobs inside cells—including helping to repair damage.

  • 4. Cancer uses PARP to grow

    If PARP is allowed to repair damage, cancer cells can survive, and tumors can continue to grow. That’s why it’s important to try and stop PARP.

  • 5. LYNPARZA may stop PARP

    That’s where LYNPARZA comes in. LYNPARZA works in 2 ways to help kill cancer cells:

    1. LYNPARZA stops PARP from repairing damage in cancer cells.
    2. LYNPARZA traps PARP on DNA to harm cancer cells.

    By preventing damage repair and harming cancer cells, LYNPARZA can help stop the tumor from growing.

  • 6. LYNPARZA may help you

    If you have an inherited BRCA mutation, LYNPARZA can help fight your HER2-negative metastatic breast cancer after previous chemotherapy, and if you’re HR-positive, after previous hormonal therapy. Take the quiz below to put your LYNPARZA knowledge to the test.

HER2=human epidermal growth factor receptor 2; HR=hormone receptor; PARP=poly (ADP-ribose) polymerase.



Cancer cell DNA





Quick review of how LYNPARZA works

Want to test your LYNPARZA knowledge? Take this quick quiz to help you review how LYNPARZA works.


 Breast cancer
 It breaks down the DNA inside cancer cells
 It tries to take shortcuts
 It helps stop and trap PARP

Important Safety Information


LYNPARZA is a prescription medicine used to treat adults who have:

  • a certain type of abnormal inherited BRCA gene, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive disease, you should have been treated with hormonal therapy. Your healthcare provider will perform a test to make sure that LYNPARZA is right for you

It is not known if LYNPARZA is safe and effective in children.


LYNPARZA may cause serious side effects, including:

Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.

Your healthcare provider will do blood tests to check your blood cell counts:

  • before treatment with LYNPARZA
  • every month during treatment with LYNPARZA
  • weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve

Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.

Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:

  • have lung or breathing problems
  • have kidney problems
  • are pregnant, become pregnant, or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage)
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after the last dose of LYNPARZA. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant
    • Males with female partners who are pregnant or able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 3 months after the last dose of LYNPARZA
    • Do not donate sperm during treatment with LYNPARZA and for 3 months after your final dose
  • are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment with LYNPARZA and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.

How should I take LYNPARZA?

  • Take LYNPARZA tablets exactly as your healthcare provider tells you
  • Do not change your dose or stop taking LYNPARZA unless your healthcare provider tells you to. Your healthcare provider may temporarily stop treatment with LYNPARZA or change your dose of LYNPARZA if you experience side effects
  • Your healthcare provider will decide how long you stay on treatment
  • Do not take more than 4 LYNPARZA tablets in 1 day. If you have any questions about LYNPARZA, talk to your healthcare provider or pharmacist
  • Take LYNPARZA by mouth 2 times a day
  • Each dose should be taken about 12 hours apart
  • Swallow LYNPARZA tablets whole. Do not chew, crush, dissolve, or divide the tablets
  • Take LYNPARZA with or without food
  • If you miss a dose of LYNPARZA, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose
  • If you take too much LYNPARZA, call your healthcare provider or go to the nearest hospital emergency room right away

What should I avoid while taking LYNPARZA?

Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.

LYNPARZA may cause serious side effects. The most common side effects of LYNPARZA are:

  • nausea or vomiting. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms
  • low number of red or white blood cells
  • stomach-area (abdominal) pain
  • dizziness
  • tiredness or weakness
  • sore throat or runny nose
  • diarrhea
  • joint, muscle, and back pain
  • headache
  • constipation
  • mouth sores
  • respiratory tract infections
  • changes in kidney function blood test
  • changes in the way food tastes
  • loss of appetite
  • low number of platelets
  • indigestion or heartburn

These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects.

You may report side effects related to AstraZeneca products by clicking here.

Please click here for complete Prescribing Information, including Patient Information (Medication Guide).